The pharmaceutical industry has seen a dramatic evolution from traditional small molecule drugs to a wide variety of therapeutic modalities. The increased complexity of therapeutics (antibody-drug conjugates, siRNA, mRNA vaccines, and antisense gene therapy) has created an unmet need in the discovery science space. Legacy systems, initially designed for small molecule drug discovery, are no longer able to support cutting edge research and development efforts. In this talk, we will discuss how to bridge the gap between chemical-based small molecule informatics system and letter-based biologics system using HELM (Hierarchical Editing Language for Macromolecules) technology. We will discuss the importance of using standardized notation, as prescribed by the Pistoia Alliance and IUPAC, and the registration and secure sharing of HELM monomers for de novo structure identification of macromolecules. Finally, we will address some of the unique challenges and solutions which have been proposed for HELM implementation in both industry and academic environments.